Latest News by Industry
SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $6.9 million in its third quarter.
On a per-share basis, the San Diego-based company said it had a loss of 26 cents.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share.
The pharmaceutical company posted revenue of $41.7 million in the period, which fell short of Street forecasts. Four analysts surveyed by Zacks expected $49.2 million.
Arcturus Therapeutics shares have declined 41% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $18.74, a fall of slightly more than 4% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ARCT at https://www.zacks.com/ap/ARCT